Merck (MRK.N) reported today that it is buying ARQL for over a 100% premium from Friday's closing price (https://reut.rs/341eQv1). This...

Today, an advisory committee appointed by the FDA met and voted to recommend to the FDA that it expands the label for AMRN's...

Central nervous system (CNS) disorder drug development is a particularly difficult branch of biopharma drug development. ITCI has...

GLYC has what is likely to be a binary event reading out later this year, likely in the next 45 days, with the phase 3 readout of its...

Congrats to ARQL and especially CLL (a type of blood cancer) patients on the impressive early-stage data presented today at a poster...

Congrats to CARA on a well-executed and positive Phase 3 trial of KORSUVA injection for reduction of pruritis (severe itching) in...

Congrats to ARRY on positive data for mutant BRAF colorectal cancer (CRC). This interim data should lead to FDA/EMA approvals in this...

We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011....

Q2 2019 Amp Core™ Quarterly Report Published 4/17/19 OVERVIEW We were looking for a rebound in small/mid ("smid") cap biopharma stocks in...

(For a longer version of this article, with more detailed legal facts, please CLICK HERE.) Concert (CNCE) and Incyte (INCY) have been...

Sangamo (SGMO) provided an update today on its clinical programs, with its first clinical data for its Phase I Hemophilia A (gene...

SUPN reported mixed positive results today for its final phase 3 trial for SPN-812 in attention deficit hyperactivity disorder (ADHD).*...

Congrats to ALDX on strong Ph3 data in allergic conjunctivitis (AC) not only showing statistical significant area under curve for ocular...

AIMT is seeking approval for AR101 as a treatment to reduce the risk of anaphylaxis following accidental exposure to peanuts in children...

Proteostasis (PTI) is scheduled to release data from 4 early-phase trials in Cystic Fibrosis (CF) imminently (i.e. this quarter) for all...

Based on robust Ph2B and Ph3 (Japan) data in prior trials with similar design, it appears highly likely that UROV's Vibegron will meet...

Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest...

ARQL pleasantly surprised investors yesterday on its quarterly call by giving two positive clinical trial updates. First, and most...

We eagerly await Ascendis's (ASND) imminent phase 3 top-line results for its weekly growth hormone therapeutic candidate, TransCon GH....

Congrats to Horizon Pharma (HZNP) and especially patients with thyroid eye disease (TED), on the positive phase 3 results reported...